Sangamo Therapeutics Inc (NASDAQ: SGMO)’s stock price has soared by 8.72 in relation to previous closing price of 1.49. Nevertheless, the company has seen a gain of 75.95% in its stock price over the last five trading days. seekingalpha.com reported 2024-10-23 that Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approval. The global Fabry Disease treatment market size is expected to be worth $3.34 billion by 2030. Data from the phase 1/2 STARR study, using isaralgagene civaparvovec targeting patients with Fabry Disease, is expected in the first half of 2025.
Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?
The 36-month beta value for SGMO is also noteworthy at 1.22. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SGMO is 198.84M, and at present, short sellers hold a 9.16% of that float. The average trading volume of SGMO on October 25, 2024 was 11.94M shares.
SGMO’s Market Performance
SGMO’s stock has seen a 75.95% increase for the week, with a 91.83% rise in the past month and a 76.72% gain in the past quarter. The volatility ratio for the week is 21.38%, and the volatility levels for the past 30 days are at 11.51% for Sangamo Therapeutics Inc The simple moving average for the last 20 days is 64.78% for SGMO’s stock, with a simple moving average of 130.95% for the last 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $1.50, previously predicting the price at $5. The rating they have provided for SGMO stocks is “Underperform” according to the report published on April 28th, 2023.
Wedbush gave a rating of “Outperform” to SGMO, setting the target price at $16 in the report published on February 27th of the previous year.
SGMO Trading at 79.97% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.47% of loss for the given period.
Volatility was left at 11.51%, however, over the last 30 days, the volatility rate increased by 21.38%, as shares surge +85.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +80.34% upper at present.
During the last 5 trading sessions, SGMO rose by +74.32%, which changed the moving average for the period of 200-days by +191.82% in comparison to the 20-day moving average, which settled at $0.9823. In addition, Sangamo Therapeutics Inc saw 198.18% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -20.22 for the present operating margin
- -0.43 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -20.34. The total capital return value is set at -4.6. Equity return is now at value -194.05, with -119.44 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at -5.96. The debt to equity ratio resting at 1.23. The interest coverage ratio of the stock is 2.18.
Currently, EBITDA for the company is -92.1 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 27.84. The receivables turnover for the company is 21.13for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
In summary, Sangamo Therapeutics Inc (SGMO) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
